Ariad ARIA Stock up on Phase 3 Trial - Ridaforolimus

September 14, 2009 - Shares of Ariad Pharmaceuticals Inc. (ARIA) are set to open higher today as the company has come out with positive phase 3 trial data.


ARIAD Announces Result of First Interim Analysis of Phase 3 Succeed Trial of Oral Ridaforolimus, Its Investigational mTOR Inhibitor, in Metastatic Sarcomas

Trial To Continue Enrolling Patients And Proceed To Completion

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the first interim efficacy analysis as specified by the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to full patient enrollment and completion. The DMC made this recommendation after reviewing the pre-specified statistical analyses and available data on the safety and efficacy of oral ridaforolimus.

The DMC review comprised approximately one-third of the total number of progression-free survival events anticipated in the trial. The safety and efficacy of oral ridaforolimus is being evaluated in patients with metastatic soft-tissue and bone sarcomas who have achieved a favorable response to chemotherapy. The primary end-point of the trial is progression-free survival. Full Article

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free